Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-hodgkin lymphoma

Zeppa, Pio; Marino, G.; Troncone, Giancarlo; Fulciniti, Franco; Renzo, Amalia De; Picardi, Marco; Benincasa, Giulio; Rotoli, Bruno; Vetrani, A; Palombini, Lucio

doi:10.1002/cncr.11903

Cited by 124 publications

(168 citation statements)

References 34 publications

Supporting

Mentioning

152

Contrasting

Order By: Relevance

“…Recent studies have shown that the diagnostic accuracy of FNA improves significantly when used in combination with immunohistochemistry, flow cytometry, or excisional biopsy. [45][46][47] In the NCCN guidelines, FNA results alone are not suitable for making an initial diagnosis of NHL, although they may be sufficient to establish relapse. However, in certain circumstances, when a lymph node is not easily accessible, a combination of core biopsy and FNA in conjunction with appropriate ancillary techniques (polymerase chain reaction [PCR] for IgH and T-cell receptor gene rearrangements and FISH for major translocations) may be sufficient for diagnosis.…”

Section: Diagnosismentioning

confidence: 99%

Non-Hodgkin’s Lymphomas

Ad¹,

Js²,

Rh³

et al. 2010

J Natl Compr Canc Netw

223

View full text Add to dashboard Cite

OverviewNon-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B-, T-, or natural killer (NK) lymphocytes. In the United States, B-cell lymphomas represent 80% to 85% of all cases, with 15% to 20% being T-cell lymphomas; NK lymphomas are very rare. In 2009, an estimated 65,980 new cases of NHL will be diagnosed and 19,500 will die of the disease.1 NHL is the sixth leading site of new cancer cases among men and fifth among women, accounting for 4% to 5% of new cancer cases and 3% to 4% of cancer-related deaths. Non-Hodgkin's Lymphomas Clinical Practice Guidelines in OncologyKey Words NCCN Clinical Practice Guidelines, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, marginal zone lymphoma, mucosaassociated lymphoid tissue lymphoma, diagnosis, treatment, hematopathology, immunohistochemistry, treatment guidelines, staging evaluation, lymphoma pathology (JNCCN 2010;8:288-334) NCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation is based on lowerlevel evidence and there is uniform NCCN consensus. Category 2B: The recommendation is based on lowerlevel evidence and there is nonuniform NCCN consensus (but no major disagreement). Category 3: The recommendation is based on any level of evidence but reflects major disagreement. Please NoteThese guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.These guidelines are copyrighted by the National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of the NCCN © 2010. Disclosures for the NCCN Non-Hodgkin's Lymphomas Guidelines PanelAt the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through 2008, this information was published in an aggregate statement in JNCCN and online. Furthering NCCN's commitment to public transparency, this disclosure process has now been expanded by listing all potential conflicts of interest respective to each individual expert panel member.Individual disclosures for the NCCN Non-Hodgkin's Lymphomas Guidelines Panel members can be found on page 334. (To view the most recent version of these guideli...

show abstract

Section: Diagnosismentioning

confidence: 99%

Non-Hodgkin’s Lymphomas

Ad¹,

Js²,

Rh³

et al. 2010

J Natl Compr Canc Netw

223

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that the diagnostic accuracy of FNA improves significantly when it is used in combination with immunohistochemistry and flow cytometry. [22][23][24] In the NCCN Guidelines, FNA results alone are not suitable for making an initial diagnosis of NHL, although it may be sufficient to establish relapse. However, in certain circumstances, when a lymph node is not easily accessible, a combination of core biopsy and FNA in conjunction with appropriate ancillary techniques (polymerase chain reaction [PCR] for IGHV and/or T-cell receptor [TCR] gene rearrangements; FISH for major translocations; immunophenotypic analysis) may be sufficient for diagnosis.…”

Section: Diagnosismentioning

confidence: 99%

Non-Hodgkin's Lymphomas

Zelenetz

Abramson

Advani

et al. 2011

J Natl Compr Canc Netw

164

View full text Add to dashboard Cite

show abstract

“…Recent studies have demonstrated that the diagnostic accuracy of fine-needle aspiration cytology (FNAC) may improve significantly when FNAC is used in combination with flow cytometry (FCM) or immunohistochemistry (4). FNAC offers several advantages: The procedure is quick, inexpensive and the aspiration procedure exhibits very few complications (5).…”

Section: Introductionmentioning

confidence: 99%

Secondary B-cell lymphoma diagnosed by fine-needle aspiration cytology and flow cytometry following penile carcinoma: A case report

Wang

Qiu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract.The number of studies reporting lymphoma as a secondary tumor has gradually increased. However, few studies have reported that occurrence of lymphoma as a secondary tumor following treatment for penile carcinoma, particularly cases in which the lymphoma was diagnosed by fine-needle aspiration cytology and flow cytometry. The present study reports the case of a 62-year-old male patient who was troubled with frequent urination and repeated chest tightness for 5 years. The diagnosis upon admission was penile carcinoma. Two months subsequent to the tumor removal surgery, enlarged lymph nodes were extracted from the patient using fine-needle biopsy, to be analyzed using light microscopy and flow cytometry. Smear results indicated a large number of abnormal cells scattered in the right axillary lymph node. Flow cytometry immunophenotyping of fine-needle aspiration samples indicated the increased expression of cluster of differentiation (CD)79a, CD19, CD20, CD38, κ chain and human leukocyte antigen-DR, which supported a diagnosis of B-cell lymphoma. Thus, the patient was diagnosed with B-cell lymphoma based on the results of the fine-needle aspiration biopsy and flow cytometry. The method of diagnosis and causes of therapy-related leukemia are discussed in the present report.

show abstract

Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-hodgkin lymphoma

Cited by 124 publications

References 34 publications

Non-Hodgkin’s Lymphomas

Non-Hodgkin’s Lymphomas

Non-Hodgkin's Lymphomas

Secondary B-cell lymphoma diagnosed by fine-needle aspiration cytology and flow cytometry following penile carcinoma: A case report

Contact Info

Product

Resources

About